Which statement describes ropivacaine compared to bupivacaine?

Which statement describes ropivacaine compared to bupivacaine?

• A. Less cardiotoxicity, but much more expensive
• B. Higher potency
• C. Longer duration with lower toxicity
• D. Lower cost

Answer: (A)

Ropivacaine is designed to be a safer alternative to bupivacaine in terms of cardiac toxicity. It’s the pure S(-)-enantiomer and has lower lipid solubility, which means it interacts less with cardiac sodium channels at toxic concentrations. That translates to less risk of cardiotoxic effects for a given level of local anesthesia. The trade-off is cost: producing and marketing the pure enantiomer is more expensive, so ropivacaine tends to be pricier than bupivacaine. Potency and duration are not markedly better; ropivacaine is usually less potent and has a similar (or slightly shorter) duration of action compared with bupivacaine. So the statement describing ropivacaine as having less cardiotoxicity but much more expensive best captures the key difference.

Ropivacaine is designed to be a safer alternative to bupivacaine in terms of cardiac toxicity. It’s the pure S(-)-enantiomer and has lower lipid solubility, which means it interacts less with cardiac sodium channels at toxic concentrations. That translates to less risk of cardiotoxic effects for a given level of local anesthesia. The trade-off is cost: producing and marketing the pure enantiomer is more expensive, so ropivacaine tends to be pricier than bupivacaine. Potency and duration are not markedly better; ropivacaine is usually less potent and has a similar (or slightly shorter) duration of action compared with bupivacaine. So the statement describing ropivacaine as having less cardiotoxicity but much more expensive best captures the key difference.